ArticleNorthern clinics of Istanbul2025
Microwave ablation for hepatocellular carcinoma: A single-center experience and outcomes.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMicrowave ablation (MWA) has emerged as a minimally invasive treatment for hepatocellular carcinoma (HCC), offering a promising alternative for patients ineligible for surgical resection. This study aims to evaluate the efficacy, safety, and clinical outcomes of MWA in a single-center cohort, focusing on treatment success, recurrence rates, and long-term survival.
methodsA retrospective analysis was conducted on 54 patients who underwent percutaneous ultrasound-guided MWA for HCC between January 2019 and December 2023. Patient demographics, tumor characteristics, and procedural outcomes were assessed. Treatment success was defined as complete ablation confirmed by contrast-enhanced imaging one month post-procedure. Local tumor progression (LTP) and recurrence rates were evaluated during follow-up. Survival outcomes were analyzed based on follow-up data, considering overall survival and recurrence-free survival rate.
resultsA total of 71 tumors were treated in 54 patients. Complete ablation was achieved in 91.5% of tumors following the initial or secondary procedure. LTP was observed in 16.6% of patients during follow-up. No major complications were reported. The median follow-up period was 36 months, and survival outcomes were comparable to those reported for other ablative techniques. No statistically significant correlation was found between tumor size and ablation success (p>0.05).
conclusionMWA is an effective and safe treatment modality for HCC, demonstrating high technical success and acceptable recurrence rates. These findings support the continued integration of MWA in multidisciplinary HCC management, particularly for patients ineligible for surgery. Further research with larger cohorts and longer follow-up is needed to optimize patient selection and refine ablation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.